Cantor Fitzgerald Predicts Higher Earnings for CVS Health

Key Points

• Cantor Fitzgerald has increased its FY2025 earnings estimate for CVS Health from $6.12 to $6.36 per share, anticipating further growth of $6.99 per share in FY2026.
• CVS Health recently reported quarterly earnings of $1.81 per share, surpassing the consensus estimate by $0.35, with an 8.4% year-over-year revenue increase.
• The company announced a quarterly dividend of $0.665 per share, reflecting a yield of 4.3% and a dividend payout ratio of 74.30%.

CVS Health Corporation (NYSE:CVS - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of CVS Health in a research report issued to clients and investors on Friday, August 1st. Cantor Fitzgerald analyst S. James now forecasts that the pharmacy operator will earn $6.36 per share for the year, up from their previous estimate of $6.12. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Cantor Fitzgerald also issued estimates for CVS Health's FY2026 earnings at $6.99 EPS.

Several other analysts have also recently weighed in on the stock. UBS Group dropped their price target on shares of CVS Health from $71.00 to $67.00 and set a "neutral" rating for the company in a research note on Tuesday, July 22nd. Bernstein Bank dropped their price target on shares of CVS Health from $78.00 to $72.00 and set a "market perform" rating for the company in a research note on Wednesday, July 16th. Royal Bank Of Canada increased their price target on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research note on Monday, May 5th. Robert W. Baird increased their price target on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Finally, Truist Financial increased their price target on shares of CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and an average target price of $75.11.

CVS Health Stock Up 0.7%

Shares of NYSE CVS opened at $62.52 on Monday. The company has a 50-day moving average of $64.56 and a 200 day moving average of $64.01. CVS Health has a 12-month low of $43.56 and a 12-month high of $72.51. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock has a market cap of $79.30 billion, a PE ratio of 17.46, a P/E/G ratio of 0.86 and a beta of 0.58.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. During the same quarter in the prior year, the company earned $1.83 EPS. CVS Health's revenue was up 8.4% compared to the same quarter last year.

Institutional Investors Weigh In On CVS Health

A number of hedge funds have recently added to or reduced their stakes in CVS. Avion Wealth lifted its holdings in CVS Health by 99.0% during the 2nd quarter. Avion Wealth now owns 380 shares of the pharmacy operator's stock worth $26,000 after buying an additional 189 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in shares of CVS Health in the 2nd quarter valued at $30,000. Bell Investment Advisors Inc raised its holdings in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after purchasing an additional 248 shares in the last quarter. McIlrath & Eck LLC raised its holdings in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares in the last quarter. Finally, Roxbury Financial LLC raised its holdings in shares of CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 202 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction on Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director directly owned 12,007 shares in the company, valued at $764,845.90. This represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.22% of the stock is currently owned by company insiders.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.3%. CVS Health's dividend payout ratio is 74.30%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.